Collectively, the screening, clinical management and ideally prevention of ARIA-H during Aβ immunotherapy trials are potentially relevant to limiting clinical deterioration, especially in Alzheimer’s disease patients with co-occurring CAA or APOE ε4 carriers who are at increased risk.43 This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.